دورية أكاديمية
Metabolism, toxicity and management of fruquintinib: a novel drug for metastatic colorectal cancer.
| العنوان: | Metabolism, toxicity and management of fruquintinib: a novel drug for metastatic colorectal cancer. |
|---|---|
| المؤلفون: | Patell K; Hematology and Oncology Fellow, University Hospitals Seidman Cancer Center, Case Western Reserve University, Cleveland, OH, USA., Mears VL; GI Oncology Clinical Pharmacist Specialist, University Hospitals Seidman Cancer Center, Case Western Reserve University, Cleveland, OH, USA., Storandt MH; Internal Medicine Resident, Mayo Clinic, Rochester, MN, USA., Mahipal A; University Hospitals Seidman Cancer Center, Case Western Reserve University, Cleveland, OH, USA. |
| المصدر: | Expert opinion on drug metabolism & toxicology [Expert Opin Drug Metab Toxicol] 2024 Apr; Vol. 20 (4), pp. 197-205. Date of Electronic Publication: 2024 Mar 20. |
| نوع المنشور: | Journal Article; Review |
| اللغة: | English |
| بيانات الدورية: | Publisher: Informa Healthcare Country of Publication: England NLM ID: 101228422 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1744-7607 (Electronic) Linking ISSN: 17425255 NLM ISO Abbreviation: Expert Opin Drug Metab Toxicol Subsets: MEDLINE |
| أسماء مطبوعة: | Publication: London : Informa Healthcare Original Publication: London : Ashley Publications, Ltd., c2005- |
| مواضيع طبية MeSH: | Colorectal Neoplasms*/drug therapy , Colorectal Neoplasms*/pathology , Benzofurans*/administration & dosage , Benzofurans*/adverse effects , Benzofurans*/pharmacology , Antineoplastic Agents*/adverse effects , Antineoplastic Agents*/administration & dosage , Antineoplastic Agents*/pharmacokinetics , Antineoplastic Agents*/pharmacology , Neoplasm Metastasis* , Protein Kinase Inhibitors*/adverse effects , Protein Kinase Inhibitors*/administration & dosage , Protein Kinase Inhibitors*/pharmacology , Protein Kinase Inhibitors*/pharmacokinetics , Quinazolines*/adverse effects , Quinazolines*/administration & dosage , Quinazolines*/pharmacokinetics , Quinazolines*/pharmacology , Receptors, Vascular Endothelial Growth Factor*/antagonists & inhibitors, Humans ; Animals ; Prognosis |
| مستخلص: | Introduction: Colorectal cancer (CRC) is the third most diagnosed cancer globally and despite therapeutic strides, the prognosis for patients with metastatic disease (mCRC) remains poor. Fruquintinib is an oral vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitor (TKI) targeting VEGFR -1, -2, and -3, and has recently received approval by the U.S. Food and Drug Administration for treatment of mCRC refractory to standard chemotherapy, anti-VEGF therapy, and anti-epidermal growth factor receptor (EGFR) therapy. Areas Covered: This article provides an overview of the pre-clinical data, pharmacokinetics, clinical efficacy, and safety profile of fruquintinib, as well as the management of clinical toxicities associated with fruquintinib. Expert Opinion: Fruquintinib is a valuable additional treatment option for patients with refractory mCRC. The pivotal role of vigilant toxicity management cannot be understated. While fruquintinib offers a convenient and overall, well-tolerated treatment option, ongoing research is essential to determine its efficacy in different patient subsets, evaluate it in combination with chemotherapy and immunotherapy, and determine its role in earlier lines of therapy. |
| فهرسة مساهمة: | Keywords: Colon cancer; fruquintinib; metastatic cancer; rectal cancer; targeted therapy; vascular endothelial growth factor |
| المشرفين على المادة: | 0 (Benzofurans) 0 (Antineoplastic Agents) 0 (Protein Kinase Inhibitors) 49DXG3M5ZW (HMPL-013) 0 (Quinazolines) EC 2.7.10.1 (Receptors, Vascular Endothelial Growth Factor) |
| تواريخ الأحداث: | Date Created: 20240318 Date Completed: 20240425 Latest Revision: 20240503 |
| رمز التحديث: | 20240504 |
| DOI: | 10.1080/17425255.2024.2332364 |
| PMID: | 38497279 |
| قاعدة البيانات: | MEDLINE |
PDF full text from Publisher | تدمد: | 1744-7607 |
|---|---|
| DOI: | 10.1080/17425255.2024.2332364 |